Article
Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.
Cell death & disease - 28 Mar 2022
Vicencio J M, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen S H, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan J N E, Flores-Borja F, Barber P R, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley J A, Parsons M, Arnold J N, Ameer-Beg S, Quezada S A, Yarden Y, Sala G, Ng T
Abstract excerpt
Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and the third-generation tyrosine kinase inhibitor (TKI) osimertinib. This new drug extends lifespan by 9-months vs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.